Sanofi

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Innovent Biologics announced China's NMPA approval of DOVBLERON®, a next-gen ROS1 TKI for previously treated ROS1-positive NSCLC. DOVBLERON®, Innovent's 13th commercial product, addresses unmet needs, especially for patients with brain metastases and resistance to prior ROS1 TKIs. A second NDA for DOVBLERON® was accepted for ROS1-positive NSCLC patients without prior ROS1 TKI treatment.

Sanofi acquires exclusive rights to develop and commercialize aficamten, a next-in-class cardiac myosin inhibitor for hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals. Cytokinetics remains eligible for up to $150 million in milestone payments and royalties on future sales. Aficamten has received Breakthrough Therapy Designation for symptomatic obstructive hypertrophic cardiomyopathy and is under various clinical trials.

Roche's experimental Parkinson’s drug, prasinezumab, failed another key trial but shows potential in levodopa users, prompting further exploration. Despite mixed results, Roche plans continued studies and data evaluation.

DelveInsight's 'Pompe Disease Pipeline Insights, 2024' covers 15+ companies and 20+ pipeline drugs, including clinical and nonclinical stage products, with insights on product type, stage, route of administration, and molecule type. Key companies include Spark Therapeutics, Amicus Therapeutics, and Novartis AG. Report highlights recent clinical trial results and emerging therapies.

RNA therapy offers precision targeting, rapid development, broad therapeutic potential, non-permanent effects, and customization for personalized medicine. Clinical trials highlight RNA therapy's promise in treating genetic disorders, cancers, and infectious diseases, with mRNA vaccines demonstrating agility during COVID-19. Advances in RNA delivery systems and platform technology enhance scalability and versatility, paving the way for effective treatments.

Sanofi and Teva's RELIEVE UCCD phase 2b study met primary endpoints for duvakitug, a TL1A antibody, in treating moderate-to-severe IBD. Duvakitug showed clinical remission in UC and endoscopic response in CD, with no safety signals. Phase 3 development is planned.

Teva and Sanofi's Phase IIb RELIEVE UCCD study showed positive results for duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, in treating moderate-to-severe IBD. Duvakitug met primary endpoints in UC and CD patients, with 36.2% (low-dose) and 47.8% (high-dose) achieving clinical remission in UC, and 26.1% (low-dose) and 47.8% (high-dose) showing endoscopic response in CD, compared to placebo. The study is ongoing, with a long-term extension and maintenance period.

Sanofi and Teva announced positive phase IIb RELIEVE UCCD study results for duvakitug, an anti-TL1A therapy for Ulcerative Colitis and Crohn's disease, meeting primary endpoints. Plans for a late-stage study and detailed results presentation are underway. Shares of both companies surged post-announcement.

Teva and Sanofi's Phase 2b study of duvakitug, a TL1A antibody for IBD, showed 47.8% remission in ulcerative colitis and Crohn's disease patients, outperforming Merck and Roche's treatments. The partnership aims for duvakitug to achieve blockbuster status with $1 billion annual sales.